Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes
暂无分享,去创建一个
Ton N Schumacher | Fridtjof Lund-Johansen | F. Lund-Johansen | T. Schumacher | S. Wälchli | Weiwen Yang | J. Olweus | Weiwen Yang | Johanna Olweus | L. Fallang | Sébastien Wälchli | S. Kumari | Lars-Egil Fallang | Shraddha Kumari
[1] T. Schumacher,et al. Dissection of T-cell antigen specificity in human melanoma. , 2012, Cancer research.
[2] C. Perreault,et al. Origin and plasticity of MHC I-associated self peptides. , 2012, Autoimmunity reviews.
[3] L. Cooper. Off-the-shelf T-cell therapy. , 2010, Blood.
[4] J. Melenhorst,et al. Allogeneic HLA-A*02–Restricted WT1-Specific T Cells from Mismatched Donors Are Highly Reactive but Show Off-Target Promiscuity , 2011, The Journal of Immunology.
[5] D. Crawford,et al. Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. , 2005, The Lancet. Oncology.
[6] S. Stevanović,et al. Quantitative aspects of T cell activation--peptide generation and editing by MHC class I molecules. , 1999, Seminars in immunology.
[7] T. Schumacher,et al. T-cell-receptor gene therapy , 2002, Nature Reviews Immunology.
[8] Morten Nielsen,et al. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11 , 2008, Nucleic Acids Res..
[9] Hans J. Stauss,et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer , 2001, Nature Immunology.
[10] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[11] H. Stauss,et al. Generation of human tumor‐reactive cytotoxic T cells against peptides presented by non‐self HLA class I molecules , 1998, European journal of immunology.
[12] G. Ogg,et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. , 2004, Blood.
[13] H. Eisen,et al. A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein , 1992, Cell.
[14] D. Busch,et al. Allorestricted T lymphocytes with a high avidity T‐cell receptor towards NY‐ESO‐1 have potent anti‐tumor activity , 2009, International journal of cancer.
[15] Jerzy K. Kulski,et al. The HLA genomic loci map: expression, interaction, diversity and disease , 2009, Journal of Human Genetics.
[16] J. Drijfhout,et al. Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. , 2011, Blood.
[17] H. Rammensee,et al. Peptides naturally presented by MHC class I molecules. , 1993, Annual review of immunology.
[18] J. Shabanowitz,et al. Identification of endogenous peptides recognized by in vivo or in vitro generated alloreactive cytotoxic T lymphocytes: distinct characteristics correlated with CD8 dependence , 2001, European journal of immunology.
[19] B. Malissen,et al. How much can a T‐cell antigen receptor adapt to structurally distinct antigenic peptides? , 2007, The EMBO journal.
[20] F. Lund-Johansen,et al. Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif , 2010, Leukemia.
[21] Arie Admon,et al. The Human Immunopeptidome Project, a Suggestion for yet another Postgenome Next Big Thing , 2011, Molecular & Cellular Proteomics.
[22] J. Leunissen,et al. The Human Leukocyte Antigen–presented Ligandome of B Lymphocytes* , 2013, Molecular & Cellular Proteomics.
[23] Bernard Malissen,et al. What do TCR-pMHC crystal structures teach us about MHC restriction and alloreactivity? , 2003, Trends in immunology.
[24] C. Melief,et al. Identification of T-cell epitopes for cancer immunotherapy , 2007, Leukemia.
[25] S. Wälchli,et al. T cells raised against allogeneic HLA‐A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells , 2012, International journal of cancer.
[26] T. Schumacher,et al. Design and use of conditional MHC class I ligands , 2006, Nature Medicine.
[27] Ton N Schumacher,et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers , 2009, Nature Methods.
[28] A. Swerdlow,et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells , 2002, The Lancet.
[29] F. Lund-Johansen,et al. Dendritic Cells Engineered to Express Defined Allo‐HLA Peptide Complexes Induce Antigen‐specific Cytotoxic T Cells Efficiently Killing Tumour Cells , 2009, Scandinavian journal of immunology.
[30] W. Uckert,et al. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. , 2010, The Journal of clinical investigation.
[31] O. Lund,et al. NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence , 2007, PloS one.
[32] V. Engelhard,et al. Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. , 2002, Molecular immunology.
[33] M. Perales,et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. , 2010, Blood.
[34] I. Sandlie,et al. A Practical Approach to T-Cell Receptor Cloning and Expression , 2011, PloS one.
[35] A. Swerdlow,et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. , 2007, Blood.
[36] J. Melenhorst,et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. , 2010, Blood.
[37] M. Gross,et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes , 2007, Nature Immunology.
[38] D. Busch,et al. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. , 2009, Blood.
[39] H. Kolb. Graft-versus-leukemia effects of transplantation and donor lymphocytes. , 2008, Blood.
[40] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] E. Gilboa,et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.